A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

Keyphrases

• Phase II Study 100%
• Anaphylaxis 100%
• Acalabrutinib 100%
• Bruton's Tyrosine Kinase 100%
• Tyrosine Kinase Inhibition 100%
• Peanut Protein 60%
• Peanut 60%
• FDA-approved Drugs 40%
• IgE-mediated 40%
• Food Challenge 40%
• Clinical Reactivity 40%
• Clinically Significant 20%
• Signaling Pathway 20%
• Allergic Reaction 20%
• Open-label Trial 20%
• Preventive Treatment 20%
• Placebo-controlled Trial 20%
• Adverse Events 20%
• Essential Enzymes 20%
• Twice Daily 20%
• Rest Period 20%
• Food Allergens 20%
• B-cell Malignancies 20%
• Pharmacologic Targets 20%
• Peanut Allergy 20%
• Bruton Tyrosine Kinase Inhibitor 20%
• Systemic Allergic Reaction 20%
• Patient Tolerance 20%
• Non-serious 20%
• Threshold Dose 20%
• Tolerated Dose 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Peanut 100%
• Bruton Tyrosine Kinase 100%
• Anaphylaxis 100%
• Acalabrutinib 83%
• Allergic Reaction 33%
• Immunoglobulin E 33%
• Adverse Event 16%
• Placebo 16%
• Bruton Tyrosine Kinase Inhibitor 16%
• Open-Label Trial 16%
• Food Allergen 16%
• Peanut Allergy 16%